HUTCHMED H1 FY26 net income drops to $15.9 million; revenue rises 0.22% to $278.3 million

• HUTCHMED posted US$ 15.93 million net income, down from US$ 454.95 million a year earlier after a 2025 divestment gain.
• Revenue was US$ 278.29 million, little changed from a year earlier.
• Oncology/Immunology revenue rose 13% to US$ 162.32 million, driven by ELUNATE revenue up 40% to US$ 47.1 million.
• Cash, cash equivalents, short-term investments totaled US$ 1.37 billion at June 30, 2026.
• Management highlighted China in-market sales up 32% to US$ 94.4 million, citing improved salesforce productivity after last year’s streamlining.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260814-12284100), on August 14, 2026, and is solely responsible for the information contained therein.